Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02178241 · OUTCOME

Overall Survival

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery · Source last updated 2019-12-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From start of treatment until death from any cause ,up to 36 months

What was measured

Estimated using the product-limit method of Kaplan and Meier.

Groups in this outcome

Treatment (Eribulin Mesylate and Gemcitabine Hydrochloride)

Patients receive 1000mg/m\^2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 1.4mg/m\^2 eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Eribulin Mesylate: Given IV Gemcitabine Hydrochloride: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Eribulin Mesylate and Gemcitabine Hydrochloride)24

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Eribulin Mesylate and Gemcitabine Hydrochloride)11.9Not reported5.620.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5.6
        upper Limit
        20.4
        value
        11.9
denoms
  1. counts
    1. group Id
      OG000
      value
      24
    units
    Participants
description
Estimated using the product-limit method of Kaplan and Meier.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive 1000mg/m\^2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 1.4mg/m\^2 eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Eribulin Mesylate: Given IV Gemcitabine Hydrochloride: Given IV
    id
    OG000
    title
    Treatment (Eribulin Mesylate and Gemcitabine Hydrochloride)
param Type
MEDIAN
reporting Status
POSTED
time Frame
From start of treatment until death from any cause ,up to 36 months
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice